Salix and its lead drug Xifaxan have Valeant sniffing around a deal

Will a buyer scoop up Salix ($SLXP) and its gastrointestinal portfolio soon? Valeant Pharmaceuticals ($VRX) is reportedly eyeing a bid for the troubled drugmaker, which last year confessed to an inventory snafu that overstated its sales. The cash-rich Shire ($SHPG) is also on the hunt. Sterne Agee analyts figure a buyer with GI drugs of its own--like Shire--could afford a bid at least 20% higher than Salix's standalone value of $145. Report

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.